Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Hepatocellular 6Breast Neoplasms 4Esophageal Squamous Cell Carcinoma 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Locally Advanced Gastric Cancer 2Colorectal Neoplasms 2Cervical Cancer Metastatic 2Triple Negative Breast Neoplasms 1Sarcoma 1Rectal Neoplasms 1Rectal Cancer Patients 1Rare Tumour 1Non-squamous Non-small Cell Lung Cancer 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Liposarcoma 1Laryngeal Neoplasms 1Esophageal Squamour Cell Cancer 1Esophageal Neoplasms 1Endometrial Neoplasms 1Biliary Tract Neoplasms 1Advanced Triple Negative Breast Cancer 1Advanced Pancreatic Cancer 1

Interventions

camrelizumab 1Pemetrexed 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Non-squamous Non-small Cell Lung Cancer × camrelizumab × Clear all
NCT06335355 2024-03-28

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

Shanghai Shengdi Pharmaceutical Co., Ltd

Phase 2/3 Not yet recruiting
401 enrolled
Thoracic

Non-squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡